ESMO Preceptorship on Breast Cancer

PROGRAMME

ESMO PRECEPTORSHIP

SINGAPORE 2-3 DECEMBER 2026

CO-CHAIRS

Rebecca A. Dent, Singapore

Nadia Harbeck, Germany

esmo.org

ESMO PRECEPTORSHIP PROGRAMME
BREAST CANCER

Multidisciplinary management, standards of care, therapeutic targets and future perspectives

Singapore
2-3 December 2026

CO-CHAIRS
Rebecca A. Dent, Singapore
Nadia Harbeck, Germany

SPEAKERS
Maria João Cardoso, Portugal
Shaheenah Dawood, United Arab Emirates
Belinda E. Kiely, Australia
Sung-Bae Kim, Republic of Korea
Soo Chin Lee, Singapore
Icro Meattini, Italy
Shani Paluch-Shimon, Israel
Frédérique Penault-Llorca, France

LEARNING OBJECTIVES

- To learn about screening, diagnosis and staging of breast cancer
- To learn about genetic testing and management of BRCA carriers
- To learn about the biology of breast cancer and its implications in the management of this disease
- To learn about the standard of care, management of early, locally advanced, and metastatic breast cancer in surgery, radiation therapy and systemic therapy
- To understand the crucial role of multidisciplinary care in the management of breast cancer

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For future details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This educational programme has been supported by

Daiichi-Sankyo | AstraZeneca

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org

Wednesday, 2 December 2026

09:00-09:10 10’	Welcome and introduction	
10’	Welcome and introduction	Rebecca A. Dent, SG Nadia Harbeck, DE

09:10-09:55 45’	SESSION 1 Pathology	Chair: Nadia Harbeck, DE
30’	Basics of pathology and clinically relevant biomarkers in early and metastatic breast cancer	Frédérique Penault-Llorca, FR
15’	Q&A	All

09:55-10:40 45’	SESSION 2 Communicating bad news to cancer patients	Chair: Rebecca A. Dent, SG
30’	Communicating bad news to cancer patients	Belinda E. Kiely, AU
15’	Q&A	All

10:40-11:10	Coffee break

11:10-12:45 95’	SESSION 3 HER2+ Breast cancer	Chair: Nadia Harbeck, DE
25’	Optimising (neo)adjuvant systemic therapy in HER2+ breast cancer: Where are we in escalation and de-escalation?	Sung-Bae Kim, KR
25’	Systemic therapy for HER2+ advanced breast cancer: Current state-of-the-art and future perspectives	Shaheenah Dawood, UAE
15’	Q&A	All
30’	Participants clinical case discussion (3x10’)	Faculty

12:45-13:45	Lunch

13:45-15:45 120’	SESSION 4 Luminal breast cancer	Chair: Soo Chin Lee, SG
30’	Early ER+	Nadia Harbeck, DE
30’	Metastatic breast cancer	Soo Chin Lee, SG
30’	Q&A	All
30’	Participants clinical case discussion (3x10’)	Faculty

15:45-16:15	Coffee break

16:15-17:20 65’	SESSION 5 Local-regional treatment	Chair: Nadia Harbeck, DE
25’	Surgery of the breast and the axilla: Where are we?	Maria João Cardoso, PT
25’	Radiotherapy: How short is enough?	Icro Meattini, IT
15’	Q&A	All

19:00	Networking dinner

Thursday, 3 December 2026

09:00-10:25 85’	SESSION 6 Triple Negative Breast Cancer (TNBC)	Chair: Rebecca A. Dent, SG
20’	What is the optimal therapy in TNBC according to stage at diagnosis and pathological response?	Sung-Bae Kim, KR
20’	Systemic therapy for advanced TNBC	Rebecca A. Dent, SG
15’	Q&A	All
30’	Participants clinical case discussion (3x10’)	Faculty

10:25-10:55	Coffee break

10:55-12:35 100’	SESSION 7 Breast cancer in young women	Chair: Shani Paluch-Shimon, IL
20’	Oncofertility care in young women with breast cancer	Shani Paluch-Shimon, IL
20’	Genetic testing	Soo Chin Lee, SG
20’	Breast cancer during pregnancy	Shani Paluch-Shimon, IL
10’	Q&A	All
30’	Participants clinical case discussion (3x10’)	Faculty

12:35-13:20 45’	SESSION 8 Artificial Intelligence	Chair: Nadia Harbeck, DE
30’	AI in breast cancer	Maria João Cardoso, PT
15’	Q&A	All

13:20-13:25 5’	Closing remarks	Rebecca A. Dent, SG Nadia Harbeck, DE

13:25-14:25	Lunch

Note: Each 10-minute slot for clinical case discussion includes a 5’ case presentation and a 5’ Q&A / panel discussion